Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer

Linda D. Mellby, Andreas P. Nyberg, Julia S. Johansen, Christer Wingren, Børge G. Nordestgaard, Stig E. Bojesen, Breeana L. Mitchell, Brett Sheppard, Rosalie Sears, Carl A.K. Borrebaeck

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of, 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. Patients and Methods The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. Results Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. Conclusion This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.

Original languageEnglish (US)
Pages (from-to)2887-2894
Number of pages8
JournalJournal of Clinical Oncology
Volume36
Issue number28
DOIs
StatePublished - Oct 1 2018

Fingerprint

Pancreatic Neoplasms
Biomarkers
Biopsy
Serum
Adenocarcinoma
Case-Control Studies
ROC Curve
Area Under Curve
Survival
Validation Studies
Delayed Diagnosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., ... Borrebaeck, C. A. K. (2018). Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. Journal of Clinical Oncology, 36(28), 2887-2894. https://doi.org/10.1200/JCO.2017.77.6658

Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. / Mellby, Linda D.; Nyberg, Andreas P.; Johansen, Julia S.; Wingren, Christer; Nordestgaard, Børge G.; Bojesen, Stig E.; Mitchell, Breeana L.; Sheppard, Brett; Sears, Rosalie; Borrebaeck, Carl A.K.

In: Journal of Clinical Oncology, Vol. 36, No. 28, 01.10.2018, p. 2887-2894.

Research output: Contribution to journalArticle

Mellby, LD, Nyberg, AP, Johansen, JS, Wingren, C, Nordestgaard, BG, Bojesen, SE, Mitchell, BL, Sheppard, B, Sears, R & Borrebaeck, CAK 2018, 'Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer', Journal of Clinical Oncology, vol. 36, no. 28, pp. 2887-2894. https://doi.org/10.1200/JCO.2017.77.6658
Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. Journal of Clinical Oncology. 2018 Oct 1;36(28):2887-2894. https://doi.org/10.1200/JCO.2017.77.6658
Mellby, Linda D. ; Nyberg, Andreas P. ; Johansen, Julia S. ; Wingren, Christer ; Nordestgaard, Børge G. ; Bojesen, Stig E. ; Mitchell, Breeana L. ; Sheppard, Brett ; Sears, Rosalie ; Borrebaeck, Carl A.K. / Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 28. pp. 2887-2894.
@article{5336a1ee8b3f4133bba0b8069458ade4,
title = "Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer",
abstract = "Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of, 10{\%} because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. Patients and Methods The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. Results Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. Conclusion This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.",
author = "Mellby, {Linda D.} and Nyberg, {Andreas P.} and Johansen, {Julia S.} and Christer Wingren and Nordestgaard, {B{\o}rge G.} and Bojesen, {Stig E.} and Mitchell, {Breeana L.} and Brett Sheppard and Rosalie Sears and Borrebaeck, {Carl A.K.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1200/JCO.2017.77.6658",
language = "English (US)",
volume = "36",
pages = "2887--2894",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer

AU - Mellby, Linda D.

AU - Nyberg, Andreas P.

AU - Johansen, Julia S.

AU - Wingren, Christer

AU - Nordestgaard, Børge G.

AU - Bojesen, Stig E.

AU - Mitchell, Breeana L.

AU - Sheppard, Brett

AU - Sears, Rosalie

AU - Borrebaeck, Carl A.K.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of, 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. Patients and Methods The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. Results Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. Conclusion This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.

AB - Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of, 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. Patients and Methods The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. Results Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. Conclusion This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.

UR - http://www.scopus.com/inward/record.url?scp=85054130095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054130095&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.77.6658

DO - 10.1200/JCO.2017.77.6658

M3 - Article

C2 - 30106639

AN - SCOPUS:85054130095

VL - 36

SP - 2887

EP - 2894

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -